UBS Maintains a 'Buy' on McKesson (MCK); A Closer Look at US Oncology
Tweet Send to a Friend
UBS maintains a 'Buy' on McKesson (NYSE: MCK), raises PT from $82 to $84.
UBS analyst says, "The US Oncology ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
UBS analyst says, "The US Oncology ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
